## RESTRICTION REQUIREMENT

The Examiner has required restriction under 35 U.S.C. 121 and 372 to one of the following inventions:

I Group I, claims 24-28, drawn to a method of treating a microbe-caused disease of at at least one of skin, a mucous membrane and an oral cavity.

II Group II, claims 29-33, drawn to a method of treating an inflammatory disease.

III Group III, claims 34-47, drawn to a composition comprising oil of coriander.

## ELECTION

In order to be responsive to the restriction requirement, Applicants elect, with traverse, the invention of claims **24-28** (i.e., the invention of **Group I** as identified in the Restriction Requirement).

## TRAVERSE

Applicants respectfully submit that a restriction requirement is inappropriate in this case at least with respect to the inventions of the above Groups I and III. In particular, the inventions of Groups I and III clearly have a common special technical feature.

Specifically, claims 24-28 (the invention of Group I) are directed to a method of treating or preventing a microbe-caused disease of at least one of skin, a mucous membrane and an oral cavity,

which method comprises the administration to a subject of an amount of oil of coriander which is effective for treating or preventing the microbe-caused disease. Claims 34-47 (the invention of Group III) on the other hand, are directed to a composition which comprises oil of coriander and is specifically stated to be suitable in the method of Group I. In other words, the invention of Group I makes use of the invention of Group III, establishing a strong link between both inventions. In this regard, the Examiner's attention is directed to page 6, first paragraph to page 16, third paragraph of the present specification and specifically, to page 8, second paragraph to page 9, second paragraph thereof. Specific embodiments are described in page 10, second and third paragraphs; the paragraph bridging pages 10 and 11; page 11, third and last paragraphs; page 12, first paragraph; the paragraph bridging pages 13 and 14; and page 14, second paragraph to page 16, first paragraph.

Especially from the noted passages of the present specification it can clearly be taken that the method of Group I and the composition of Group III are closely interrelated and are merely different embodiments of the same invention.

Further, even if one were to assume, *arguendo*, that the inventions of Groups I to III are distinct, the requirement for restriction should be withdrawn because there is no serious burden.

In MPEP Chapter 800, the Office sets forth its policy by which examiners are guided in requiring restriction under 35 U.S.C. § 121. Section 803 states that "[i]f the search and examination of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to distinct or independent inventions."

Applicants note that as set forth above, the inventions of Groups I to III identified in the Restriction Requirement relate generally to the use of oil of coriander for medicinal purposes. For

example, a search for the invention of Group III would cover many (if not all) areas which are relevant for the inventions of Groups I and II as well. Thus, the search burden would not be serious, and neither is it alleged in the present Restriction Requirement that the search burden would be serious.

For the above reasons alone, the present Restriction Requirement should be withdrawn, which action is respectfully requested.

Should there be any questions, the Examiner is respectfully invited to contact the undersigned at the telephone number below.

Respectfully submitted,
Matthias AUGUSTIN et al.



Neil F. Greenblum
Reg. No. 28,394

April 8, 2009
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Heribert F. Muensterer
Reg. No. 50,417